Literature DB >> 144039

Treatment of Paget's disease of bone with mithramycin.

W G Ryan.   

Abstract

The hypothesis that Paget's disease of bone is a low grade neoplastic process led us to use the cytotoxic antibiotic mithramycin in its treatment. The dramatic effects observed on the serum calcium and alkaline phosphatase, and urinary hydroxyproline are compatible with the concept that mithramycin is primarily toxic to osteoclasts. Subjective and objective clinical effects establish this agent as useful in the treatment of Paget's disease despite its observed toxicity to other organ systems.

Entities:  

Mesh：

Substances：

Year:  1977        PMID： 144039

Source DB:  PubMed          Journal:  Clin Orthop Relat Res        ISSN： 0009-921X            Impact factor:   4.176


  9 in total

1.  Medical staff conference. Paget disease of bone.

Authors: 
Journal:  West J Med       Date:  1978-09

Review 2.  Epigenetic mechanisms of neurodegeneration in Huntington's disease.

Authors:  Junghee Lee; Yu Jin Hwang; Ki Yoon Kim; Neil W Kowall; Hoon Ryu
Journal:  Neurotherapeutics       Date:  2013-10       Impact factor: 7.620

3.  [Osteitis deformans (Paget)--or a tarda-type of a hereditary hyperphosphatasia (author's transl)].

Authors:  A Enderle; S von Gumppenberg
Journal:  Arch Orthop Trauma Surg       Date:  1979-07-31

Review 4.  Principles of management of osteometabolic disorders affecting the aging spine.

Authors:  Alexander G Hadjipavlou; Paul G Katonis; Michael N Tzermiadianos; George M Tsoukas; George Sapkas
Journal:  Eur Spine J       Date:  2003-09-23       Impact factor: 3.134

5.  Clinical experience with pamidronate in the treatment of Paget's disease of bone.

Authors:  S J Gallacher; B F Boyce; U Patel; A Jenkins; S H Ralston; I T Boyle
Journal:  Ann Rheum Dis       Date:  1991-12       Impact factor: 19.103

6.  Paget's disease of bone. An update on management.

Authors:  D J Hosking
Journal:  Drugs       Date:  1985-08       Impact factor: 9.546

Review 7.  Management of osteoporosis and Paget's disease. An appraisal of the risks and benefits of drug treatment.

Authors:  C Gennari; R Nuti; D Agnusdei; A Camporeale; G Martini
Journal:  Drug Saf       Date:  1994-09       Impact factor: 5.606

Review 8.  Pharmacology and therapeutic use of calcitonin.

Authors:  J C Stevenson; I M Evans
Journal:  Drugs       Date:  1981-04       Impact factor: 9.546

9.  Identification of plicamycin, TG02, panobinostat, lestaurtinib, and GDC-0084 as promising compounds for the treatment of central nervous system infections caused by the free-living amebae Naegleria, Acanthamoeba and Balamuthia.

Authors:  Monica M Kangussu-Marcolino; Gretchen M Ehrenkaufer; Emily Chen; Anjan Debnath; Upinder Singh
Journal:  Int J Parasitol Drugs Drug Resist       Date:  2019-10-22       Impact factor: 4.284
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.